An Open-label Study to Investigate the Safety, Tolerability and Efficacy of a Single 6-hour Intravenous Infusion of AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy

The purpose of this study is to investigate the safety, tolerability and efficacy of a single 6-hour intravenous infusion of AMO-01 to treat adolescents and adults with PMS and co-morbid epilepsy. Phelan-McDermid Syndrome (PMS) is a neurodevelopmental disorder characterized by a chromosomal deletion or mutation at 22q13.3 that contains the SHANK3/ProSAP2 gene. A key co-morbidity in PMS is the presence of epilepsy. Currently there are no approved treatments for PMS. Furthermore, there has been relatively little clinical study of pharmacological interventions for PMS. AMO-01 may provide benefit to PMS patients exhibiting behavioral abnormalities and seizures.

开始日期2018-05-30

申办/合作机构

Icahn School of Medicine at Mount Sinai

NCT00730262 / Terminated临床2期

A Phase II Study of TLN-4601 in Patients With Glioblastoma Multiforme

The objective of this study is to assess the efficacy and safety of TLN-4601 used to treat patients with Glioblastoma Multiforme(GBM) that recur/progress after receiving first line systemic therapy post surgery/radiotherapy.

开始日期2008-08-01

申办/合作机构

Thallion Pharmaceuticals, Inc.

NCT00338026 / Completed临床1期

A Phase I, Dose Finding, Pharmacokinetic, and Safety Study of Continuous IV Infusion of ECO-4601 in Patients With Advanced Cancer Including an Extension Portion to Obtain Safety Data at the Highest Tolerable Dose

The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in patients with histologically confirmed solid tumors (high grade glioma, colorectal, lung, breast, ovarian, pancreatic and prostate). This study was also designed to determine the clinical pharmacokinetic profile, safety of multiple cycles of administration, and document the antitumor activity of ECO-4601.

开始日期2006-02-01

申办/合作机构

Thallion Pharmaceuticals, Inc.

100 项与 Diazepinomicin 相关的临床结果

登录后查看更多信息

100 项与 Diazepinomicin 相关的转化医学

登录后查看更多信息

100 项与 Diazepinomicin 相关的专利（医药）

登录后查看更多信息

项与 Diazepinomicin 相关的文献（医药）

2024-12-01·HGG advances

An open-label study evaluating the safety and efficacy of AMO-01 for the treatment of seizures in Phelan-McDermid syndrome

Article

作者: Grosman, Hannah ; Friedman, Kate ; Levy, Tess ; Siper, Paige M ; Horrigan, Joseph P ; Zweifach, Jessica ; Layton, Christina ; Kolevzon, Alexander ; Underwood, Slayton ; Holder, J Lloyd ; McMorn, Alison ; Silver, Hailey ; Halpern, Danielle ; Snape, Michael F

Phelan-McDermid syndrome (PMS) is a neurodevelopmental disorder caused by haploinsufficiency of the SHANK3 gene. Approximately 25% of individuals with PMS have epilepsy. Treatment of epilepsy in PMS may require multiple anticonvulsants, and in a minority of cases, seizures remain poorly controlled. Converging lines of evidence in different experimental models indicate that the Ras-ERK pathway is implicated in the pathophysiology of seizure generation and neurobehavioral symptoms in PMS. The goal of this study was to evaluate the safety, tolerability, and efficacy in treating seizures in adults and adolescents with PMS using AMO-01, a Ras-ERK pathway inhibitor . A single 6-hour intravenous infusion of AMO-01 at 120 mg/m² was administered to six participants using an open-label design. Safety was assessed during the infusion and for four weeks post-infusion. Caregivers completed seizure diaries and recorded individual seizures during a baseline period and for four weeks following the infusion. Exploratory clinical and biomarker assessments were completed throughout the study. AMO-01 was well tolerated with no serious adverse events (AEs) reported. All AEs were mild or moderate in severity. Seizures were reduced by at least 25% compared to baseline at each follow-up (Weeks 1, 2, 4). Exploratory clinical measures did not change significantly from baseline, but visual evoked potentials (VEPs) and phosphorylated ERK blood levels revealed trending changes in a subset of participants. These results provide preliminary support for the safety of AMO-01 and its efficacy in reducing seizures in adults with PMS. Future placebo-controlled studies with larger sample sizes and repeated dosing are warranted.

2022-12-01·Journal, genetic engineering & biotechnology

Bioinsecticidal activity of actinomycete secondary metabolites against the acetylcholinesterase of the legume’s insect pest Acyrthosiphon pisum: a computational study

Article

作者: Benslama, Ouided

BACKGROUND:

Acyrthosiphon pisum or pea aphid is an insect of the Aphididae family, which attacks various species of legumes such as beans and peas. This pest causes economically heavy crop losses around the world. The use of conventional chemical insecticides is the only way to control its development. However, the harmful consequences of these chemicals are well known. They pollute various compartments of the environment, thus constituting a major risk for human and environmental health. The search for a more ecological alternative, respectful of the environment is, therefore, a necessity. Actinomycetes represent a source of biologically active secondary metabolites, such as antibiotics and biopesticidal agents. In this study, 150 secondary metabolites of actinomycetes have made the objective of an in silico research by molecular docking, by screening their potential inhibitors against the enzyme acetylcholinesterase (AChE) of A. pisum.

RESULTS:

The 3D structure of AChE, unavailable in the PDB database, was first modeled using the Modeller program, then the stereochemical quality of the model was validated. The molecular docking performed by the Autodock Vina algorithm allowed the selection of two metabolites giving binding energy equal to or lower than that of the co-crystallized inhibitor tetrahydro-acridine (-10.3Kcal/mol). The top-two metabolites are diazepinomicine (-10.9 Kcal/mol), and hygromycin (-10.3 Kcal/mol). These components have shown numerous interactions with the key residues of the catalytic site of the AChE enzyme, indicating their potential to inhibit its biological activity. The environmental and health safety of these components, as well as their bioavailability, were also studied by the verification of several pharmacokinetic and ADMET criteria. Diazepinomicine has shown excellent results verifying most of the criteria studied. A 50-ns MD simulation was also performed in order to test the stability of the complexes formed.

CONCLUSIONS:

In addition to its favorable pharmacokinetic properties, the special chemical structure of diazepinomicin allows this molecule to interact intensely with AChE notably through the involvement of its two groups farnesyl diphosphate and dibenzodiazepinone which ensure several hydrogen and hydrophobic interactions, that offers very high stability to the complex AChE diazepinomicin. In conclusion, diazepinomicin can be suggested as a potential bioinsecticidal agent against the pest A. pisum.

2022-01-01·Bioorganic & medicinal chemistry letters

Synthesis and biological evaluation of BU-4664L derivatives as potential anticancer agents

Article

作者: Dong, Yue-Hui ; Liu, Zhao-Peng ; Liu, Chao ; Xu, Yuan-Yuan ; Wen, Zhao-Hui

BU-4664L is a naturally occurring N-farnesylated dibenzodiazepinone with important biological activities. Herein, we report the synthesis and antitumor evaluation of two series of BU-4664L derivatives bearing different substituent patterns on the dibenzodiazepinone core and with diverse side chains. All of the derivatives displayed micromolar activity against the human prostate cancer PC-3 cells, while lower or no activity against the human lung H460 cells. The most active derivatives were 10a and 16c which exerted antiproliferative activity against PC-3 cells with GI₅₀ values of 5.66 and 5.94 μM, respectively, and thus represent promising lead compounds for further development.

项与 Diazepinomicin 相关的新闻（医药）

2024-09-08

·精准药物

【Nature Cancer】高选择性低毒性的 MCL1 抑制剂: BRD-810

MCL1 基因在癌症中经常发生扩增，这赋予了肿瘤对当前标准治疗的耐药。因此，MCL1 是一个有吸引力的抗癌靶点。这里，分享由 Trueline Therapeutics 、拜尔医药、麻省理工学院和哈佛大学布罗德研究所等合作开发的一款 MCL1 抑制剂，其设计及临床前研究发表于近期的 Nature Cancer。BRD-810 是一款高效的选择性 MCL1 抑制剂，其关键设计原理是快速全身清除，以尽可能减少与 MCL1 抑制相关的毒性。BRD-810 在体外 4 小时内快速诱导细胞杀伤，但在 4 小时窗口内，即使在超药理学浓度下，对人诱导多能干细胞来源的心肌细胞中的细胞活力或肌钙蛋白 I 释放没有影响。尽管 BRD-810 在血浆中的停留时间很短，但 BRD-810 在血液和实体瘤模型中仍具有体内药效。总的来说，临床前数据支持这样的假设：用 BRD-810 短期抑制 MCL1 可以诱导肿瘤细胞凋亡，同时保持可接受的安全性。因此，BRD-810 将进行人体临床试验。 1. 背景介绍对程序性细胞死亡的抵抗（细胞凋亡）是癌症的一个标志。每个正常细胞都有能力感知外在和内在的应激信号，并维持促凋亡和抗凋亡因子的适当平衡，最终决定细胞的生或死。在恶性细胞中，Bcl-2 蛋白家族发挥着核心作用，而 MCL1 作为该蛋白家族的关键抗凋亡因子之一，已被确定可促进异常细胞存活。与其他抗凋亡 Bcl-2 家族成员一样，MCL1 通过与促凋亡效应蛋白（包括 BAK、BAX 或 BOK）以及 BH3 激活蛋白（如 BIM、PUMA 或 NOXA）紧密结合来防止癌细胞死亡。未结合的促凋亡效应蛋白通过在线粒体外膜上形成孔来启动细胞死亡信号级联，导致线粒体外膜电位破坏，并将 Ca2+和细胞色素c释放到胞质。这会引发不可逆的 Caspase 激活和蛋白酶水解级联，最终导致细胞死亡。除了其抗凋亡作用外，MCL1 的 N 端截短亚型还位于线粒体内膜，促进三磷酸腺苷 (ATP) 的产生，保护线粒体能量转导并确保线粒体稳态。 MCL1 的功能和表达在转录、转录后、翻译和翻译后水平上受到严格调控，使其成为半衰期较短的蛋白质，因此需要不断补充。同时，MCL1 是所有癌症中过度表达程度最高的病理蛋白之一，包括肝癌、乳腺癌、非小细胞肺癌 (NSCLC)、尿路上皮癌、胰腺癌以及胰腺癌中的实体瘤恶性肿瘤；以及血液肿瘤，包括急性髓系或慢性淋巴细胞白血病、和非霍奇金淋巴瘤。MCL1 的过度表达通常与不良预后有关，以及对放射治疗和化疗的耐药。有趣的是，MCL1 也被证明还可以介导对靶向治疗的耐药，包括常用的 BRAF 抑制剂、受体酪氨酸激酶抑制剂和多激酶抑制剂。由于这些特性，MCL1 成为癌症治疗的一个非常有吸引力的靶点。MCL1 的抑制已被证明可以恢复对各种药物的敏感性。最近开发了多种 MCL1 的抑制剂，目前正在早期临床试验中进行研究。不同结构类别的代表性Mcl-1抑制剂的结构，药效和共结晶。在过去的5−10年中，在（专利）文献中披露了各种有效的、选择性的Mcl-1抑制剂，一些化合物达到临床开发，尽临床结果喜忧参半和存在毒性。抑制Mcl-1功能需要阻断蛋白−蛋白相互作用，大多数开发的抑制剂都是相当大的分子，许多特性如Log P、PSA和MW位于“non-Lipinski”超过五规则（bRo5）区域。上图显示了这些复杂分子的化学空间，显示了过去十年中报道的具有代表性的抑制剂选择。由于MCL1抑制剂导致肌钙蛋白水平升高，存在潜在心脏毒性的担忧，一些项目的临床开发已经放缓或停止。组织特异性 MCL1 敲除模型导致线粒体呼吸功能障碍和心肌收缩力丧失，从而证明了 MCL1 与心肌疾病之间的联系。最近还报道了 MCL1 在调节心肌细胞脂肪酸氧化方面的新作用。以及对人诱导的多能干细胞 (hiPS 细胞) 衍生的心肌细胞的体外研究表明，长期暴露于各种 MCL1 抑制剂会破坏线粒体形态，并最终损害心肌细胞功能。综上所述，长期暴露 MCL1 抑制剂可能会导致靶向心脏毒性，因此需要一种有效的 MCL1 抑制剂，其暴露量足以诱导肿瘤细胞凋亡，但半衰期足够短，以缩短心脏毒性时间。例如，艾伯维的选择性 MCL-1 抑制剂 ABBV-467在肿瘤模型中有效，但与患者心肌肌钙蛋白(troponin I) 增加有关。大环 MCL-1 抑制剂 ABBV-467 基于结构的设计总结: 1. BRD-810 结合 MCL1 的 BH3 口袋 BRD-810 在药物化学研发项目中被鉴定出来，该研究的目标是平衡大环类 MCL1 抑制剂的细胞效力和体内清除率。图1a 总结了此次优化工作中的三种关键化合物。在HTRF 测定中，该化合物可与人 MCL1 蛋白可逆结合，并阻断 MCL1 与仅 BH3 蛋白 Noxa 衍生的肽之间的相互作用，IC50= 1.7 nM（化合物1）。此外，与其他抗凋亡蛋白（例如 Bcl- XL和 Bcl-2）相比，该化合物类别对 MCL1 表现出选择性，因为没有一个关键化合物影响其他 Bcl-2 家族成员与其各自的 BH3 蛋白的相互作用。与广泛的酶、受体和离子通道组相比，亦没有表现出明显的脱靶结合（PanLabs SafetyScreen panel）。从化合物1 开始进行先导化合物优化，通过向吲哚和萘部分引入卤素取代基，使 MCL1 蛋白结合亲和力提高了 20 倍（化合物2，解离常数Kd = 1.2 nM）。通过引入与大环氧原子相邻的吗啉代乙基侧链的化合物的细胞效力显著增强，被命名为 BRD-810 （未结合的 IC50 (IC50u) = 0.3 nM）。图 1：BRD-810 是抗凋亡蛋白 MCL1 的有效且选择性抑制剂该药物化学项目受益于先前描述的晶体学平台，通过生成经实验证实的 >50 独特化合物的结合姿势，以指导迭代设计和测试。晶体结构表明，BRD-810 占据了 MCL1 的 BH3 结合口袋（图1b），具有明确的电子密度和缺乏与对称相关蛋白质分子的相互作用。萘环深深嵌入主要由 M250 的运动产生的诱导结合袋中，氟原子位于该袋的底部。BRD-810 羧酸酯通过双齿氢键与 R263 结合，并通过水介导的氢键桥与 T266 结合。BRD-810 的附加吗啉基团针对螺旋 3 进行包装，主要涉及 G230、M231 和 K234。除了与化合物2相比细胞效力高出十倍之外，BRD-810 在对大鼠静脉内给药后被更快地清除，BRD-810 的平均停留时间 (MRT) 为 0.3 小时，而化合物2的平均停留时间 (MRT) 为 0.6 小时。总的来说，这些发现表明 BRD-810 可以有效且选择性地阻止促凋亡蛋白与 MCL1 结合，然后再从系统中快速清除。 2. BRD-810 触发癌细胞凋亡为了研究 BRD-810 抑制细胞中 MCL1 和促凋亡蛋白复合物结合的潜力，作者开发了一种定量 ELISA 测定法。该测定测量了 BRD-810 剂量增加和不同暴露时间点下天然 MCL1 蛋白与 BAK 或 BIM 蛋白的相互作用。BRD-810 的短期处理（最早 15 分钟）以剂量依赖性方式阻断 MCL1 与 BAK 的相互作用（图1c），并且 BRD-810 破坏 MCL1-BAK 复合物所需的 IC50计算出细胞平均为 1.2 nM。相比之下，BRD-810 对 MCL1-BIM 复合物的破坏明显具有剂量和时间依赖性（图1d ），并且需要更长的暴露时间才能完全破坏复合物，这反映出 BIM 在 MCL1 蛋白上的靶标停留时间较长。当细胞暴露于浓度不断增加的 BRD-810 时，免疫共沉淀分析显示出类似的复杂破坏动力学。接下来，研究了 MCL1 和促凋亡蛋白复合物破坏的下游细胞效应。用增加浓度的 BRD-810 处理乳腺癌细胞系 HMC1-8 会激活 caspase 3 并诱导细胞死亡。这些效应呈剂量依赖性，并且发生在相当浓度的 BRD-810 下（EC50 = 66 nM) 激活 Caspase，并抑制细胞生长(IC50 = 63 nM)(图1e,f）。BAX和BAK的敲除可保护细胞免受 BRD-810 介导的细胞凋亡和细胞杀伤的诱导。这表明BRD-810诱导的细胞死亡确实是通过激活细胞内在凋亡途径的靶向机制发生的（图1e，f）。为了证明 BRD-810 在完整细胞中的 MCL1 特异性，测量了已知与 MCL1 或 Bcl-XL相关的DLBCL 肿瘤细胞系中的 caspase 激活和生长抑制。用增加剂量的 BRD-810 处理 SU-DHL-5 和 SU-DHL-10 细胞（MCL1 依赖性细胞系）可产生强效（半胱天冬酶 EC50激活和 IC50细胞生长抑制 < 10 nM）和快速（在〜4小时内）诱导细胞凋亡，而在Bcl-XL依赖性细胞系（例如SU-DHL-4细胞）中，仅在浓度高>600倍时观察到细胞凋亡。总之，这些研究结果表明 BRD-810 是一种选择性 MCL1 抑制剂。 3. BRD-810 敏感性候选生物标志物为了全面评估 BRD-810 的抗增殖活性，使用了一种称为 PRISM 的快速、高通量多重筛选。PRISM 方法能够对代表 32 种不同癌症谱系的 700 多种细胞系进行筛选。在多种实体和血液癌症模型中观察到BRD-810以亚微摩尔浓度的抗增殖活性，包括乳腺癌、肺癌、黑色素瘤、肉瘤、淋巴瘤和白血病（图 2a）。编码 Bcl-X 的BCL2L1 水平较低和高水平的BAK表达与 BRD-810 诱导的功效相关性最强，其中BCL2L1与BAK mRNA 水平的比率在所有细胞系中提供了最佳的相关性（图2b）。图 2：BRD-810 在体外对多种癌症类型具有抗癌功效。将 BRD-810 与其他已进入临床试验的 MCL1 抑制剂进行了比较。在 MCL1 和其他 Bcl-2 家族抑制剂类别中，克服与血浆蛋白的非特异性结合是一个主要的设计挑战，并且在结构不同的 BH3 模拟物之间观察到了广泛的蛋白质结合。在 PRISM 筛选中对一系列血液学和实体瘤癌症类型鉴定为 BRD-810 敏感的细胞系，并用 MCL1 抑制剂 BRD-810、AZD5991、AMG176 或 S64315 处理，以评估它们在抗增殖 IC 50值。PRISM 筛选出的所有细胞系确实对 MCL1 抑制剂敏感，并且 BRD-810 是测试的细胞系中最有效的 MCL1 抑制剂。 4. BRD-810 的细胞杀伤动力学接下来，研究了 BRD-810 诱导的细胞杀伤的时间和剂量依赖性。这一点很重要，因为理想的 MCL1 抑制剂将提供足够的暴露来诱导 MCL1 依赖性肿瘤细胞死亡，但不会超出此范围，以便最大限度地减少靶向毒性。用不同浓度的 BRD-810 处理 MCL1 依赖性细胞系 5 分钟（表示为 0 小时）、1 小时、3 小时、6 小时或 24 小时，然后彻底清洗以去除细胞中的化合物。在24小时时间点测定抗增殖IC50值 (图3a)。在暴露持续时间为 1 小时或更短的情况下，大多数细胞系的 IC50u 远高于 10 nM，表明短期暴露需要大量 BRD-810 才能诱导有效的抗增殖作用。然而，暴露 3 小时后，癌细胞死亡严重，所有 MCL1 依赖性细胞系的 IC50u 值均低于 10 nM。重要的是，暴露时间超过 6 小时和长达 24 小时不会带来额外的好处。该结果表明约 4 小时的暴露足以杀死 MCL1 介导的肿瘤细胞，进一步暴露可能主要导致毒性而不是功效。图 3：BRD-810 诱导的杀伤动力学表明，短期 1 小时覆盖足以诱导体内抗肿瘤功效。 5. BRD-810 的体内药效根据体外鉴定的快速细胞杀伤动力学，作者假设高清除率 MCL1 抑制剂能够启动细胞凋亡并发挥体内功效。BRD-810 的药代动力学特征揭示了其快速清除，在小鼠中的半衰期为 0.6 小时（图3b），这转化为人类半衰期为 1.1 小时。为了表征 BRD-810 在体内的药效学作用，移植了 MOLP-8 多发性骨髓瘤细胞的小鼠注射了单剂量 6、12.5、25 或 50 mg·kg -1的 BRD-810，然后进行肿瘤活检在1、3、6、24、48和72小时，以允许测量裂解的caspase3水平作为细胞凋亡的指标（图3c）。BRD-810 静脉注射后 1 小时至 6 小时，所有剂量的裂解 caspase 3 水平均可检测到，这表明细胞凋亡的快速诱导，即使在化合物被肝胆转运系统从血浆中清除后，细胞凋亡仍持续存在。最大caspase诱导发生在 BRD-810 注射后约 3 小时，并且该时间依赖性在所有测试剂量中均相似。然而，caspase3的激活程度以剂量依赖性方式增加至25 mg·kg -1 ，并且在25至50 mg·kg -1之间相似，表明实现了最大的功能效果。接下来评估了 BRD-810 在相同 MOLP-8 肿瘤模型中的抗肿瘤功效（图3d）。每周一次的 BRD-810 给药导致肿瘤生长的剂量依赖性抑制，同样在 25 mg kg -1时达到最大效果。与大多数 MCL1 抑制剂一样，BRD-810 不抑制小鼠 Mcl1；因此，无法在小鼠中评估 BRD-810 的靶向毒性。然而，作为脱靶毒性的一种衡量标准，我们观察到每周一次给药后对体重没有影响（图3e）。为了了解 BRD-810 在不同癌症中更广泛的单药潜力，研究了 BRD-810 在两种血液学模型和两种实体瘤异种移植模型中的功效。在快速生长的多发性骨髓瘤异种移植模型AMO-1中，低至12.5 mg·kg -1的单剂量BRD-810在12天内诱导完全反应（图4a ）。在 SU-DHL-10 DLBCL 异种移植模型中，每周一次的 25 mg·kg -1剂量与每两周一次的 50 mg·kg -1剂量，发现较低频率、较高剂量的 BRD-810 导致肿瘤消退时间延长（图4b ）。图 4：BRD-810 在血液学和实体瘤异种移植模型中的体内功效。对于实体瘤异种移植模型，选择SNU398（肝脏）和A-427（NSCLC）肿瘤模型作为代表性实体瘤恶性肿瘤。用两次连续的30 mg·kg -1 注射（间隔2小时）处理异种移植小鼠，以在每个细胞模型中实现未结合IC 50的所需4小时覆盖。给药 2 天间隔 5 天的方式，BRD-810 在 SNU398 肝癌模型中显示出与标准护理（瑞格非尼）相当的疗效（图4c ）。对NSCLC模型A-427使用相同的治疗方案，发现BRD-810比标准化疗药物顺铂和依托泊苷的组合更大程度地引发强烈的肿瘤消退（图4d ）。鉴于 MCL1 在促进对常规和靶向治疗产生耐药性方面的作用，还研究了 BRD-810 在难治性治疗中的抗肿瘤作用，无论是作为单一药物还是与标准护理相结合。在急性髓性白血病（AML）的THP-1模型中，Bcl-2抑制剂venetoclax和阿糖胞苷均未显示出明显的单药疗效（图4e ），与难治性AML患者的临床经验非常相似。相比之下，每周给药 50 mg·kg -1 BRD-810 在单一疗法中具有强大的抗肿瘤作用。当与阿糖胞苷联合使用时，BRD-810 的疗效得到改善，治疗后 2 周内没有观察到肿瘤生长。虽然其他人之前已经确定 Venetoclax 单一疗法会诱导 MCL1 表达并产生耐药性，但 BRD-810 和 Venetoclax 的组合具有协同作用，能够在所有动物中引起完全缓解，在治疗后的 4 周内没有肿瘤复发。在 MV-4-11 异种移植小鼠中也观察到类似的功效，其中 BRD-810 与氮胞苷或维奈托克的组合即使在治疗停止后也能显着改善总体生存率。 6. BRD-810 对心肌细胞的影响小根据 MCL1 抑制剂的早期临床经验，记录 MCL1 抑制剂对正常心肌细胞的影响非常重要。研究指出了 MCL1 在心肌细胞功能中的重要作用，并且使用 BH3 模拟物的体外研究表明，长期暴露后，hiPS 细胞衍生的心肌细胞的存活率受损。因此，评估了 BRD-810 对 hiPS 细胞衍生的心肌细胞的影响，重点关注 BRD-810 在人体中的预期暴露时间。hiPS 细胞衍生的心肌细胞用 1 µM 阿霉素(对照)或两个剂量水平的 BRD-810 处理 72 小时。Caspase 激活被测量为细胞凋亡的指标，细胞活力的三个标记物（ATP 水平、乳酸脱氢酶（LDH）释放和细胞核计数）和心脏损伤的组织特异性标记（肌钙蛋白 I，troponin I）也被测量（图5a-e ）。图 5：BRD-810 对 iPS 细胞来源的心肌细胞的影响。相比之下，根据心脏毒性的五种测量方法中的任何一种，暴露于 0.1 µM 甚至 1 µM BRD-810 4 小时都不会导致心肌细胞毒性（图5a-e ）。这一结果表明，通过将暴露时间限制为发挥功效所需的最短时间，可以进一步扩大 BRD-810 等 MCL1 抑制剂的治疗窗口，并且具有快速清除曲线的化合物可能最好地实现这种瞬时抑制。为了进一步探讨 BRD-810 的心脏安全性，在犬类体内进行了短期剂量研究。犬类动物 MCL1 与人类 MCL1 高度相似，犬被输注药物 4 小时，以产生足以在多种小鼠肿瘤模型中发挥体内功效的 BRD-810 血浆水平，剂量为 3、8 和 15 mg·kg -1 ，分别相当于体外细胞培养物浓度 0.5 、 1 和 2 µM。这种 4 小时的输注每周重复一次，总共 4 周，并在研究结束时测量肌钙蛋白 I 水平。在中剂量或高剂量的任何狗的血液中均未检测到肌钙蛋白 I。在低剂量组中，仅在犬类的三个重复测量之一中观察到肌钙蛋白I轻微升高。总体而言，短期暴露于 BRD-810 是抑制 MCL1 的可行治疗方法。除了心肌肌钙蛋白测量之外，还进行了心电图检查，以证明重复给药 BRD-810 对关键心电图参数（PR、QRS、QT 和计算的 QTcV 间期）或心率没有影响（图6b-f ）。此外，在 4 周重复剂量研究结束时分析了尸检后所有犬类的心脏组织（图6a ）。与血液中肌钙蛋白 I 水平不存在增加相一致，心脏组织的组织病理学分析显示，BRD-810 治疗后没有心脏组织损伤的证据。总体而言，短期输注 BRD-810 不存在心脏毒性，表明其独特的药代动力学特征适合临床研究。图 6：反复接受 BRD-810 治疗的犬类心脏组织的组织病理学分析和心电图分析。 7. 讨论考虑到最近 MCL1 抑制剂早期临床开发过程中心脏安全信号的报道，以及 MCL1 在正常心肌细胞中的功能，关键问题是 MCL1 的抑制是否可以安全地用于癌症治疗。在这里，介绍 BRD-810，一种快速清除的 MCL1 抑制剂，在血液学和实体瘤癌症模型中具有强大的抗肿瘤功效。与其他临床阶段的 MCL1 抑制剂相比，BRD-810 与 MCL1 的 BH3 沟结合并阻断促凋亡蛋白的隔离，从而在 MCL1 依赖性细胞系中快速诱导 caspase 激活，具有更优异的效力。重要的是，尽管在血浆中的停留时间很短，但 BRD-810 的单次注射足以超过血液癌和实体癌体内模型中的抗凋亡阈值，并早在最初的 24 小时内就导致了可测量的肿瘤体积减小。由于细胞凋亡是不可逆的，因此不需要长时间暴露于 MCL1 抑制剂即可有效减少肿瘤。短暂的 MCL1 抑制，可以最大限度地减少 MCL1 靶向疗法的潜在靶向毒性。4 小时的 MCL1 抑制足以将 MCL1 依赖性细胞推向不可逆的凋亡路径，而不会严重损害其他细胞（包括心肌细胞）的活力。因此，BRD-810 这样能迅速从体循环中清除的 MCL1 抑制剂将在人体中进行验证。参考：https://www-nature-com.libproxy1.nus.edu.sg/articles/s43018-024-00814-0#Sec25 声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

临床结果放射疗法

2024-05-02

·PRNewswire

AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic Dystrophy

Company will conduct Phase 3 trial of AMO-02 (tideglusib) in adults to support a future submission for marketing authorization in Type 1 myotonic dystrophy in both adult and pediatric indications. LONDON, May 2, 2024 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with limited or no treatment options, today provided an update on plans to advance the clinical development program for AMO-02 (tideglusib), the company's investigational therapy in development for the treatment of Type 1 myotonic dystrophy (DM1), following a recent meeting with the U.S. Food and Drug Administration (FDA). Based on the input from the meeting, AMO Pharma will conduct a Phase 3 clinical trial to assess the efficacy and safety of AMO-02 in adult patients with adult-onset DM1 to support a future submission for marketing authorization for the treatment of DM1 in children, adolescents and adults. Continue Reading REACH-CDM (PRNewsfoto/AMO Pharma Limited) Results from AMO Pharma's previous REACH-CDM Phase 2/3 clinical study (the "REACH-CDM Study") involving children and adolescents with congenital-onset DM1 showed that AMO-02 was generally safe and well tolerated during the study, with no reported severe adverse events (SAEs) related to treatment. The primary and secondary outcome measures based on clinician administered subjective ratings showed an unexpected placebo effect that may have masked some beneficial effects of treatment. Further post hoc analysis as reviewed with the FDA indicates that there is sufficient evidence to support the continued development of tideglusib for the treatment of DM1 with agreement that AMO Pharma will now advance a Phase 3 study in adults with the adult-onset version of DM1. During the meeting, FDA reviewed data from the REACH-CDM Study to assess the efficacy and safety of treatment with AMO-02 in children and adolescents with congenital DM1. The FDA also gave feedback on the design of the new Phase 3 clinical trial for adult patients with adult onset DM1. In this study in adult onset DM1, outcome measures will be similar to those that showed benefit in the REACH-CDM Study. Following discussion with the FDA, AMO Pharma will plan a future submission for approval in children, adolescents and adults with myotonic dystrophy based on a package of safety and efficacy data from the new Phase 3 trial in adults combined with efficacy, pharmacokinetic and safety data from AMO Pharma's REACH-CDM Study. "We are pleased with the outcome of the productive discussions we had with the FDA regarding next steps for AMO-02 and continue to feel strongly that this innovative therapy can represent a significant advance in the treatment of patients with DM1, whether they are children, adolescents or adults," said Alan Rubino, executive chair at AMO Pharma. "We are now focused on progressing a new clinical study in adults with adult-onset DM1. We are very grateful to the FDA and to the patients, families, clinicians and investors who have supported our research thus far and we look forward to working with the community to advance this program as rapidly as possible. We will make an announcement regarding the start date and site locations for the adult onset DM1 study shortly." "The results of the REACH-CDM Study showed measures of efficacy benefit across multiple symptom areas, and we are very excited that this clinical development program will continue to move forward," said Hanns Lochmuller, investigator in the REACH-CDM Study at Children's Hospital of Eastern Ontario, Canada. "We remain very hopeful that this investigational therapy can have a transformative impact on the health of patients living with this ultra-rare, severe muscular dystrophy in the years ahead." About AMO-02 AMO-02 (tideglusib) is an investigational therapy in development for the treatment of DM1 with a dual mechanism disrupting the pathogenic RNA repeat in DM1and inhibiting excess levels of the kinase GSK3β. The REACH-CDM Study was a double-blind, placebo-controlled, randomized study in children and adolescents with congenital DM1 intended to support a future submission for marketing authorization in congenital DM1. The study included 56 participants at leading specialist sites in the US, Canada, New Zealand and Australia. Data associated with functional and objective measures were collected during the study, including motor and muscle assessments (10 meter walk/run, myometry, lip strength and lean muscle mass as assessed by DXA scan), cognitive performance (Peabody Picture Vocabulary Test, NIH Toolbox Picture Sequence Memory Test, NIH Toolbox Dimensional Change Card Sort Test), adaptive (real world) function (Vineland Adaptive Behavior Communication Scale, Vineland Adaptive Behavior Daily Living Scale, Vineland Adaptive Behavior Socialization Scale), bone density (DXA scan) and creatine kinase measurements. In post-hoc analyses more participants showed a positive response following AMO-02 treatment than placebo on 10 of the 12 of these measures. Treatment with AMO-02 was associated with clinically significant improvements in walking and cognition and significant effects on objective biomarkers of muscle and neuronal integrity. AMO-02 also showed significant improvement compared to placebo on a Multi-Domain Responder Index integrating clinically significant responses on measures of ambulation, muscle strength, cognitive performance, activities of daily living and an objective biomarker. Primary analyses of subjective rating assessments showed a placebo effect. Patients from this study and treatment naïve patients with congenital or juvenile onset DM1 are currently being supported in the REACH CDM-X open label extension safety study. About AMO Pharma AMO Pharma is a clinical-stage specialty biopharmaceutical company working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare and severe childhood onset neurogenetic disorders with limited or no treatment options. In addition to developing AMO-02 for DM1, the company is also progressing AMO-01 as a clinical stage treatment for Phelan-McDermid syndrome and AMO-04 as a clinic-ready potential medicine for Rett syndrome and related disorders. AMO-02, AMO-01 and AMO-04 are investigational medicines that have not yet been approved for the treatment of patients anywhere in the world. Advice provided to AMO Pharma by regulators is under the condition that any scientific advice given is not legally binding with regards to any future application for the product concerned. Furthermore, advice cannot be taken as indicative of any future agreed position. For more information, please visit the AMO Pharma website at . Media contact: Holly Stevens Berry & Company Public Relations [email protected] 212-253-8881 SOURCE AMO Pharma Limited

临床3期临床结果临床2期

2024-02-15

·PRNewswire

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

LONDON, Feb. 15, 2024 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with limited or no treatment options, today announced a collaboration with Population Health Research Institute (PHRI), a joint institute of McMaster University and Hamilton Health Sciences in Canada, to advance a clinical proof of concept trial to assess the efficacy of AMO-02 (tideglusib), AMO Pharma's investigational oral glycogen synthase kinase 3 beta (GSK3β) inhibitor, in the treatment of genotype positive arrhythmogenic cardiomyopathy (ACM). The study, entitled "Targeted Therapy with Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy" (TaRGET), will be led by the research team at PHRI and will involve collaboration with multiple organizations in addition to AMO Pharma including the Hearts in Rhythm Organization (HiRO). Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio. "It can be a helpless feeling to carry a gene for ACM and know that, no matter how you live your life, you may someday develop a deadly form of heart disease," said Jason Roberts, scientist at PHRI and TaRGET study principal investigator, adding, "Encouraged by earlier studies in animal models, we are hopeful that tideglusib may serve as an effective treatment that can dramatically improve the health of people living with ACM. The TaRGET trial is a critical first step in evaluating this potential." ACM is a form of genetic heart disease characterized by scarring in the heart muscle. This scarring increases the risk of dangerously fast heart rhythms that can lead to sudden cardiac death (SCD). There are currently no approved medical therapies that have been shown to prevent progression of ACM. An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for ACM patients considered at high risk for SCD. In prior research, a high-throughput screen of bioactive compounds against a zebrafish model of ACM identified a small molecule classified as a GSK3β inhibitor that successfully prevented and rescued the phenotype, findings that have subsequently been reproduced in a series of ACM murine models. GSK3β is an enzyme that modulates the activity of a broad spectrum of intracellular signaling pathways, including the canonical Wnt/β-catenin pathway whose suppression has been suggested to exert an important role in ACM pathogenesis. "As we continue to advance our research to assess the potential benefits of AMO-02 in the treatment of myotonic dystrophy, we are very pleased to be supporting this landmark research effort in ACM with the outstanding team at PHRI," said Mike Snape, chief scientific officer at AMO Pharma. "Based on extensive research that highlights the proven MOA of AMO-02 as a clinically safe and well tolerated GSK3β inhibitor, we look forward to progress in advancing this promising program that can bring new hope to people living with ACM and their families in the years ahead. This new data has the potential to build on the cardiac efficacy data previously reported in studies conducted in Duchenne muscular dystrophy by Professor Val Fajardo's team at Brock University." About AMO Pharma AMO Pharma is a clinical-stage specialty biopharmaceutical company working to identify and advance promising therapies for the treatment of serious and debilitating diseases in patient populations with significant areas of unmet need, including rare and severe childhood onset neurogenetic disorders with limited or no treatment options. In addition to developing AMO-02 for myotonic dystrophy, the company is also progressing AMO-01 as a clinical stage treatment for Phelan-McDermid syndrome and AMO-04 as a clinic-ready potential medicine for Rett syndrome and related disorders. AMO-02, AMO-01 and AMO-04 are investigational medicines that have not yet been approved for the treatment of patients anywhere in the world. Advice provided to AMO Pharma by regulators is under the condition that any scientific advice given is not legally binding with regards to any future application for the product concerned, neither on the part of MHRA/Commission on Human Medicines (CHM) nor on the Company. Furthermore, advice cannot be taken as indicative of any future agreed position. For more information, please visit the AMO Pharma website at . Media Contact Holly Stevens Berry & Company Public Relations 212 253 8881 [email protected] Logo -

临床研究

100 项与 Diazepinomicin 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12420

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
癫痫	临床2期	美国	Icahn School of Medicine at Mount Sinai	2018-05-30
Phelan-McDermid 综合征	临床2期	美国	AMO Pharma Ltd.初创企业	2018-03-30
多形性胶质母细胞瘤	临床2期	美国	Thallion Pharmaceuticals, Inc.	2008-08-01
多形性胶质母细胞瘤	临床2期	加拿大	Thallion Pharmaceuticals, Inc.	2008-08-01
复发性胶质母细胞瘤	临床2期	美国	Thallion Pharmaceuticals, Inc.	2008-08-01
复发性胶质母细胞瘤	临床2期	加拿大	Thallion Pharmaceuticals, Inc.	2008-08-01
晚期癌症	临床1期	加拿大	Thallion Pharmaceuticals, Inc.	2006-02-01
乳腺癌	临床1期	加拿大	Thallion Pharmaceuticals, Inc.	2006-02-01
结直肠癌	临床1期	加拿大	Thallion Pharmaceuticals, Inc.	2006-02-01
高级别胶质瘤	临床1期	加拿大	Thallion Pharmaceuticals, Inc.	2006-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03493607 (CTgov)	临床2期	癫痫 \| Phelan-McDermid 综合征	6	AMO-01	糧構鏇餘鹹艱網衊窪築(顧鹹糧衊築餘夢鑰淵襯) = 獵蓋願鏇積構襯鏇衊築衊築製窪製顧壓鏇鬱鹽 (觸構遞願壓餘鏇鏇膚製, 餘淵鏇築鑰廠鬱餘艱積 ~ 糧艱膚膚鏇憲襯壓壓觸) 更多	-	2021-06-22